|
References Auerbach R, Lewis R, Shinners B, Kubai L, Akhtar N. Angiogenesis Assays: A Critical Overview. Clin Chem. 2003;49:32-40
Boo YC, Hwang J, Sykes M, Michell BJ, Kemp BE, Lum H, Jo H. Shear stress stimulates phosphorylation of eNOS at Ser(635) by a protein kinase A-dependent mechanism. Am J Physiol Heart Circ Physiol. 2002;283:1819-1828.
Bergers G, Brekken R, McMahon G, Vu TH, Itoh T, Tamaki K, Tanzawa K, Thorpe P, Itohara S, Werb Z, Hanahan D. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2:737-744.
Carmeliet P. Angiogenesis in health and disease. Nat Med. 2003;9:653–660.
Dawson DL, Cutler BS, Hiatt WR, Hobson RW 2nd, Martin JD, Bortey EB, A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-30.
Development of a novel, weighted, quantifiable stroke scale: Japan stroke scale. Gotoh F, Terayama Y, Amano T. Stroke. 2002;33:1171
D''Angelo FA, Ramacciato G, Aurello P, Lauro S, Caramitti A, Lalle M, Magri M. Alternative insertion sites for permanent central venous access devices. Eur J Surg Oncol. 1997 Dec;23(6):547-9.
Dimmeler S, Zeiher AM. Nitric oxide-an endothelial cell survival factor. Cell Death Differ. 1999;6:964-968. Review.
Elam MB, Heckman J, Crouse JR. Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication. Arterioscler Thromb Vasc Biol. 1998;18:1942-1947.
Favot L, Keravis T, Holl V, Le Bec A, Lugnier C. VEGF-induced HUVEC migration and proliferation are decreased by PDE2 and PDE4 inhibitors. Thromb Haemost. 2003;90:334-43.
Folkman J, Shing Y. Angiogenesis. J Biol Chem. 1992;267:10931–10934.
Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR, Tsichlis PN. The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell. 1995;81:727-736.
Fulton D, Gratton JP, McCabe TJ, Fontana J, Fujio Y, Walsh K, Franke TF, Regulation of endothelium-derived nitric oxide production by the protein kinase Akt.Papapetropoulos A, Sessa WC. Nature. 1999;399:597-601.
Griffioen AW, Molema G. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation. Pharmacol Rev. 2000;52:237-68.
Goto F, Goto K, Weindel K, Folkman J. Synergistic effects of vascular endothelial growth factor and basic fibroblast growth factor on the proliferation and cord formation of bovine capillary endothelial cells within collagen gels. Lab Invest. 1993;69:508-517.
Hashimoto, A., Miyakoda, G., Hirose, Y., Mori, T. Activation of endothelial nitric oxide synthase by cilostazol via a camp/protein kinase aand phosphatidylinositol 3-kinase/akt-dependent mechanism. Atherosclerosis. 2006; 189, 350–357.
Ikeda Y. Antiplatelet therapy using cilostazol, a specific PDE3 inhibitor. Thromb Haemost. 1999;82:435-8. Review.
Judah F, Yuen S. Angiogenesis. J Bio Chem. 1992;267:10931-10934.
Karsten S. The pharmacology of cilostazol. Diabetes, Obes and Metabo.. 2002;4:S14-S19.
Kambayashi J, Liu Y, Sun B, Shakur Y, Yoshitake M, Czerwiec F. Cilostazol as a unique antithrombotic agent. Curr Pharm Des. 2003;9:2289-2302.
Kim KY, Moon JI, Lee EJ, Lee YJ, Kim IB, Park CK, Oh SJ, Chun MH. The effect of L-arginine, a nitric oxide synthase substrate, on retinal cell proliferation in the postnatal rat. Dev Neurosci. 2002;24:313-321.
Kohda N, Tani T, Nakayama S. Effect of cilostazol, a phosphodiesterase III inhibitor, on experimental thrombosis in the porcine carotid artery. Thromb Res. 1999; 96:261-268.
Kwon SU, Cho YJ, Koo JS. Cilostazol Prevents the Progression of the Symptomatic Intracranial Arterial Stenosis: The Multicenter Double-Blind Placebo-Controlled Trial of Cilostazol in Symptomatic Intracranial Arterial Stenosis. Stroke. 2005; 36:782-786. Kimura Y, Tani T, Kanbe T, Watanabe K. Effect of cilostazol on platelet aggregation and experimental thrombosis. Arzneimittelforschung. 2005;36:782-786.
Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation. 2004;109:II27-33.
Lee JH, Oh GT, Park SY, Choi JH, Park JG, Kim CD, Lee WS, Rhim BY, Shin YW, Hong KW. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther. 2005;313:502-9.
Liu Y, Fong M, Cone J, Wang S, Yoshitake M, Kambayashi J. Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol. 2000;36:351-360.
Li A, Dubey S, Varney ML, Dave BJ, Singh RK. IL-8 directly enhanced endothelial cell survival, proliferation, and matrix metalloproteinases production and regulated angiogenesis. J Immunol. 2003;170:3369-3376.
Lugnier, C. Cyclic nucleotide phosphodiesterase (pde) superfamily: a new target for the development of specific therapeutic agents. Pharmacol. Ther. 2006;109,366–398
Ma PC, Blaszkowsky L, Bharti A, Ladanyi A, Kraeft SK, Bruno A, Skarin AT, Chen LB, Salgia R. Circulating tumor cells and serum tumor biomarkers in small cell lung cancer. Anticancer Res. 2003;23:49-62. Review.
Morishita R, Aoki M, Nakamura S, Matsushita H, Tomita N, Hayashi S, Moriguchi A, Matsumoto K, Nakamura T, Higaki J, Ogihara T. Potential role of a novel vascular modulator, hepatocyte growth factor (HGF), in cardiovascular disease: characterization and regulation of local HGF system. J Atheroscler Thromb. 1997;4:12-19.
Munoz, Chapuli, R., A. R. Quesada, M. Angel . Angiogenesis and signal transduction in endothelial cells. Cell Mol Life Sci . 2004; 61:2224-2243
Murohara T, Horowitz JR, Silver M, Tsurumi Y, Chen D, Sullivan A, Isner JM. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation. 1998;97:99-107.
Murphy G. Matrix metalloproteinases and their inhibitors. Acta Orthop Scand Suppl. 1995;266:55-60. Review.
Nakamura T. Definition and classification of osteoporotic vertebral fracture. Clin Calcium. 2001;11:1176-1181
Nakamura T, Kanda S, Yamamoto K, Kohno T, Maeda K, Matsuyama T, Kanetake H. Increase in hepatocyte growth factor receptor tyrosine kinase activity in renal carcinoma cells is associated with increased motility partly through phosphoinositide 3-kinase activation.Oncogene. 2001;20:7610-7623.
Netherton SJ, Maurice DH. Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: implications in angiogenesis. Mol Pharmacol. 2005;67:263-272.
Norgen L, Hiatt WR, Harris KA, Lammer J, TASC II Working Group. TASC II section F on revascularization in PAD. J Endovase Ther. 2007;14:734-742.
Park, S.Y., Lee, J.H., Kim, C.D., Lee, W.S., Park, W.S., Han, J., Kwak, Y.G., Kim, K.Y., Hong, K.W. Cilostazol suppresses superoxide production and expression of adhesion molecules in human endothelial cells via mediation of camp-dependent protein kinase-mediated maxi-k channel activation. J. Pharmacol. Exp. Ther. 2006;317:1238–1245. Papapetropoulos A, Desai KM, Rudic RD, Mayer B, Zhang R, Ruiz-Torres MP, García-Cardeña G, Madri JA, Sessa WC. Nitric oxide synthase inhibitors attenuate transforming-growth-factor-beta 1-stimulated capillary organization in vitro. Am J Pathol. 1997;150:1835-44.
Park SY, Lee JH, Kim YK, Kim CD, Rhim BY, Lee WS, Hong KW. Cilostazol prevents remnant lipoprotein particle-induced monocyte adhesion to endothelial cells by suppression of adhesion molecules and monocyte chemoattractant protein-1 expression via lectin-like receptor for oxidized low-density lipoprotein receptor activation. J Pharmacol Exp Ther. 2005;312:1241-1248.
Peter C. Angiogenesis in health and disease. Na Med. 2003;9:653-660
Prior BM, Yang HT, Terjung RL. What makes vessels grow with exercise training? J Appl Physiol. 2004;97:1119-28.
Robless P, Mikhailidis DP, Stansby GP. Cilostazol for peripheral arterial disease. Cochrane Database Syst Rev. 2008 ;1:CD003748.
Schnaper HW, Kopp JB, Poncelet AC, Hubchak SC, Stetler-Stevenson WG, Klotman PE, Kleinman HK. Increased expression of extracellular matrix proteins and decreased expression of matrix proteases after serial passage of glomerular mesangial cells. J Cell Sci. 1996;109:2521-8.
Sepúlveda P, Martinez-León J, García-Verdugo JM. Neoangiogenesis with endothelial precursors for the treatment of ischemia. Transplant Proc. 2007;39:2089-94. Review. Shiojima I, Walsh K. Role of Akt signaling in vascular homeostasis and angiogenesis. Circ Res. 2002;90:1243-1250. Review.
Staels B, Koenig W, Habib A, Merval R, Lebret M, Torra IP, Delerive P, Fadel A, Chinetti G, Fruchart JC, Najib J, Maclouf J, Tedgui A. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature. 1998;393:790-793.
Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol. 2003;200:448-464. Review.
Tamai Y, Takami H, Nakahata R, Ono F, Munakata A. Comparison of the effects of acetylsalicylic acid, ticlopidine and cilostazol on primary hemostasis using a quantitative bleeding time test apparatus. Haemostasis. 1999;29:269-276.
Tjon JA, Riemann LE. Treatment of intermittent claudication with pentoxifylline and cilostazol. Am J Health Syst Pharm. 2001;58:485-93:quiz494-496.
Yancopoulos GD, Davis S, Gale NW, Rudge JS, Wiegand SJ, Holash J. Vascular-specific growth factors and blood vessel formation. Nature. 2000;407:242–248.
Yao R, Cooper GM. Requirement for phosphatidylinositol-3 kinase in the prevention of apoptosis by nerve growth factor. Science. 1995;267:2003-2006.
Yi-Lu Y, Wen-Zhen S, Wei-Ping Z, Meng-Ling W, Yu Z, San-Hua F, Li-Ying L, Qi Z, Yue-Ping Y, Er-Qing W. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries. Eur J Pharmacol. 2007;557:23-31
Zhang XP, Tada H, Wang Z, Hintze TH. cAMP signal transduction, a potential compensatory pathway for coronary endothelial NO production after heart failure. Arterioscler Thromb Vasc Biol. 2002;22:1273-8.
|